A phase I/II study (NCT03278782) was conducted to evaluate the efficacy and safety of pembrolizumab in combination with the HDAC inhibitor romidepsin in the treatment of patients with R/R PTCL. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.